PE20120781A1 - Formulacion de omeprazol farmaceutica estable para administracion oral - Google Patents

Formulacion de omeprazol farmaceutica estable para administracion oral

Info

Publication number
PE20120781A1
PE20120781A1 PE2012000062A PE2012000062A PE20120781A1 PE 20120781 A1 PE20120781 A1 PE 20120781A1 PE 2012000062 A PE2012000062 A PE 2012000062A PE 2012000062 A PE2012000062 A PE 2012000062A PE 20120781 A1 PE20120781 A1 PE 20120781A1
Authority
PE
Peru
Prior art keywords
agent
oral administration
stable pharmaceutical
omeprazole
omeprazole formulation
Prior art date
Application number
PE2012000062A
Other languages
English (en)
Spanish (es)
Inventor
Erik Juvonen
Louis Massimo Micolucci
Original Assignee
Vetegen Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43465734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120781(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vetegen Llc filed Critical Vetegen Llc
Publication of PE20120781A1 publication Critical patent/PE20120781A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PE2012000062A 2009-07-20 2010-07-20 Formulacion de omeprazol farmaceutica estable para administracion oral PE20120781A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22689009P 2009-07-20 2009-07-20

Publications (1)

Publication Number Publication Date
PE20120781A1 true PE20120781A1 (es) 2012-06-27

Family

ID=43465734

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000062A PE20120781A1 (es) 2009-07-20 2010-07-20 Formulacion de omeprazol farmaceutica estable para administracion oral

Country Status (11)

Country Link
US (1) US8530500B2 (enExample)
EP (1) EP2456439A4 (enExample)
JP (1) JP2012533633A (enExample)
AU (1) AU2010276404A1 (enExample)
CA (1) CA2768024A1 (enExample)
CL (1) CL2012000169A1 (enExample)
CO (1) CO6491061A2 (enExample)
EC (1) ECSP12011618A (enExample)
IN (1) IN2012DN00359A (enExample)
PE (1) PE20120781A1 (enExample)
WO (1) WO2011011351A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140113667A (ko) * 2011-12-16 2014-09-24 아토픽스 테라퓨릭스 리미티드 호산구성 식도염의 치료를 위한 crth2 길항제 및 양성자 펌프 저해제의 조합
GB201306720D0 (en) 2013-04-12 2013-05-29 Special Products Ltd Formulation
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
GB2561355A (en) * 2017-04-10 2018-10-17 Eaststone Ltd Pharmaceutical composition and a method for manufacturing the same
CN107397719A (zh) * 2017-08-16 2017-11-28 洛阳市兽药厂 一种畜禽用奥美拉唑可溶性粉剂及其制备工艺
CA3073957A1 (en) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. Pharmaceutical compositions comprising sepiapterin and uses thereof
JP7515092B2 (ja) * 2017-10-18 2024-07-12 北海道公立大学法人 札幌医科大学 抗菌剤のスクリーニング方法
GB2585628A (en) * 2019-05-08 2021-01-20 Alkaloid Ad Pharmaceutical formulation
GB2616663A (en) * 2022-03-18 2023-09-20 Alkaloid Ad Skopje Pharmaceutical formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
SK286371B6 (sk) * 1999-02-23 2008-08-05 Merck & Co., Inc. Farmaceutický prostriedok
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
US20050239845A1 (en) * 2004-04-16 2005-10-27 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US9050368B2 (en) * 2007-11-13 2015-06-09 Meritage Pharma, Inc. Corticosteroid compositions

Also Published As

Publication number Publication date
EP2456439A4 (en) 2012-12-26
ECSP12011618A (es) 2012-04-30
CA2768024A1 (en) 2011-01-27
AU2010276404A1 (en) 2012-02-02
CO6491061A2 (es) 2012-07-31
WO2011011351A3 (en) 2011-05-19
EP2456439A2 (en) 2012-05-30
US8530500B2 (en) 2013-09-10
IN2012DN00359A (enExample) 2015-05-22
CL2012000169A1 (es) 2012-08-31
WO2011011351A2 (en) 2011-01-27
JP2012533633A (ja) 2012-12-27
US20110015233A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
CY1123023T1 (el) Υδατικη φαρμακευτικη μορφοποιηση ταπενταδολης για χορηγηση απο το στομα
CO6491061A2 (es) Formulacion de omeprazol farmaceutica estable para administracion oral
PE20110010A1 (es) Formulaciones liquidas de fenilefrina
NZ596657A (en) Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof
ECSP11011555A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
EA201170543A1 (ru) Жидкий фармацевтический состав, содержащий парацетамол
ECSP11011561A (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
CL2011001225A1 (es) Formulacion farmaceutica en solucion acuosa que comprende desde 1% hasta 5% (p/v) de una sal de diclofenaco, desde 3% hasta 30% (p/v) de al menos un polioxialquilen ester de hidroxido de acido graso y un co-solvente seleccionado de etanol, propanol, glicerol, propilenglicol entre otros.
ECSP10010167A (es) Composiciones oftálmicas novedosas
AR080491A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
TNSN08061A1 (en) Liquid formulations
CR20110435A (es) Formulaciones de 4-amino-2-(2,6-dioxopiperidina-3-il) isoindolina-1,3-diona
AR025434A1 (es) Formulacion farmaceutica con contenido de derivados de benzamida, con solubilidad y absorcion oral mejoradas
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
WO2011110939A3 (en) Pharmaceutical compositions of substituted benzhydrylpiperazines
UY33075A (es) Derivados de ciclohexano y usos de los mismos
MX354647B (es) Composicion farmaceutica anticonvulsiva transnasal que comprende un anticonvulsivante escasamente soluble.
CO6321158A2 (es) Formulacion oral
CL2004000899A1 (es) Composicion farmaceutica que contiene la sal sodica de telmisartan y un agente diuretico y procedimiento de preparacion.
AR082049A1 (es) Formulaciones liquidas de rupatadina fumarato
AR066905A1 (es) Administracion intranasal de asenapina y composiciones farmaceuticas correspondientes
AR117718A2 (es) Mejoramientos en composiciones farmacéuticas, y relacionados con ellas
AR078785A1 (es) Formulaciones de bazedoxifeno con antioxidantes
CO2019003632A2 (es) Formulaciones de buprenorfina de liberación sostenida
PE20131137A1 (es) Composiciones nasales de vitamina b12

Legal Events

Date Code Title Description
FC Refusal